Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 14/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485015 | 0.88 | MAP3K14 (0.44) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CG | |
| SCHEMBL1484994 | 0.84 | MAP3K14 (0.55) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL16074591 | 0.82 | PIK3CA (0.42) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CG | |
| SCHEMBL17613233 | 0.82 | MAP3K14 (0.42) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CG | |
| SCHEMBL1484978 | 0.81 | MAP3K14 (0.43) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CG | |
| SCHEMBL19594359 | 0.81 | PIK3CA (0.43) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL18655441 | 0.80 | MAP3K14 (0.41) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CG | |
| SCHEMBL1485127 | 0.80 | PIK3CA (0.42) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CG | |
| SCHEMBL1485055 | 0.80 | PIK3CA (0.42) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL12696762 | 0.79 | PIK3CA (0.41) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | MAP3K14 210/4885PIK3CD 7/4885PIK3R1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.